Aditxt and Evofem partner to launch endometriosis diagnostic in 2025
The Pearsanta’s MET diagnostic test uses a blood-based biomarker for detecting mitochondrial DNA for diagnosing endometriosis ...
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, ...
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, ...
Investornewsbreaks Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
Aditxt (NASDAQ: ADTX) , an innovation platform dedicated to accelerating promising health innovations, has reported that its Acquisition target, Evofem Biosciences (OTCQB: EVFM) , a women's health ...
Investing3d
Aditxt secures new financing and expands collaboration with Evofem
Aditxt, Inc., a pharmaceutical company specializing in immune system reprogramming, has entered into a series of strategic agreements, as per a recent 8-K filing with the Securities and Exchange ...
Investing3d
Aditxt secures new financing and expands collaboration with Evofem
Aditxt, Inc., a pharmaceutical company specializing in immune system reprogramming, has entered into a series of strategic agreements, as per a recent 8-K filing with the Securities and Exchange ...
Morningstar6d
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
Pearsanta’s MET is Seeking to Become the First and Only Validated and Commercialized Blood-based Biomarker Test for Endometriosis Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company ...
Nasdaq6d
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
MOUNTAIN VIEW, Calif. & SAN DIEGO--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating ...
Yahoo Finance9d
Aditxt, Inc. (ADTX)
MOUNTAIN VIEW, Calif. & SAN DIEGO, September 09, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating health innovations, and women’s health ...
Stockhouse6d
Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
Pearsanta’s MET is Seeking to Become the First and Only Validated and Commercialized Blood-based Biomarker Test for Endometriosis Aditxt, Inc. (NASDAQ: ADTX) ...
Business Wire17d
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
MOUNTAIN VIEW, Calif. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating ...